The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain's Serious Fraud Office re-examines funding model

Tue, 24th May 2016 17:13

By Kirstin Ridley

LONDON, May 24 (Reuters) - The Serious Fraud Office (SFO),Britain's leading fraud and corruption investigator andprosecutor, said on Tuesday it was re-examining a funding modelthat has been criticised for risking weakening investigationsand delaying cases.

So-called "blockbuster funding", under which the agency canrequest extra cash for costly cases directly from thegovernment, was criticised in a report published on Tuesday bythe Crown Prosecution Service Inspectorate (CPSI), which reviewsthe effectiveness of the SFO's structures and governance.

The CPSI said such a model, which allows the SFO to shore upits staffing levels with external experts for big cases, coulddamage investigations, did not provide value for money andprevented the agency from building future expertise in-house.

It said that when it inspected the agency 21 percent ofstaff were not permanent employees.

"There is therefore an inherent lack of consistency in (SFO)teams, which becomes particularly problematic because of thelengthy nature of SFO investigations," the report said. "Thisdisruption increases the risk of delay in cases and may weakenthe investigative strategy going forward."

The CPSI report, which praised the SFO board for improvingthe reputation of the agency externally over the last fouryears, also suggested other reforms such as a smaller managementboard, appointing a chief executive, clearer reporting anddelegation lines for committees and holistic risk management.

SFO head David Green said in an emailed statement that theagency was "giving new consideration" to a funding model he hassaid in the past is not perfect, but which "does the job".

He said the SFO was also carefully considering recommendations such as appointing a CEO or chief operatingofficer and changing the structure of the management board.

Legal experts have already criticised a funding model theyargue could lead to political interference with cases that canconcern influential blue-chip British companies. The SFO'scurrent caseload includes investigations into Barclays,Rolls-Royce and GSK.

The SFO operates on a core annual budget of around 35million pounds ($51 mln), although extra cash injections to payfor costly cases have pushed that up to around 50 million poundsa year over the last few years.

Its biggest and costliest cases have included theinvestigation into the alleged manipulation of financialbenchmarks such as Libor (London interbank offered rate), whichto date has yielded one conviction and one guilty plea.

Five former Barclays traders are on trial at Southwark CrownCourt and further trials of individuals accused of manipulatingEuribor (euro interbank offered rate) are expected to begin nextyear. ($1 = 0.6838 pounds) (Reporting by Kirstin Ridley; Editing by Susan Fenton)

More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.